Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest adenosine Stories

Alzheimer's Disease
2014-04-07 08:44:44

University of Bonn A team of researchers working with Prof. Dr. Christa E. Muller from the University of Bonn demonstrates a positive effect on tau deposits As part of a German-French research project, a team led by Dr. Christa E. Müller from the University of Bonn and Dr. David Blum from the University of Lille was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease. The two-years project was supported with 30,000 Euro from...

Heart Attack Patients May Soon Have Side Effect-Free Drug Option
2014-03-12 06:36:52

April Flowers for redOrbit.com - Your Universe Online A new drug designed to stop a heart attack in its tracks, while reducing the damage caused, all without side effects, is one step closer to development thanks to a group of Melbourne scientists from Monash University. New hope for thousands of people who experience heart attacks and heart failure is provided by the study, published in a recent issue of Proceedings of the National Academy of Sciences. A team of scientists, led by...

2013-12-31 08:22:46

Following the Successful Utilization of A3 Adenosine Receptor Biomarker in Can-Fite's Phase IIb Rheumatoid Arthritis Study PETACH TIKVA, Israel, Dec. 31, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the following: The Company's subsidiary, OphthaliX Inc. (OTCQB: OPLI), will conduct a retrospective analysis...

2013-12-31 08:22:44

PETACH TIKVA, Israel, Dec. 31, 2013 /PRNewswire/ -- OphthaliX Inc. (OTCQB: OPLI), announced today that it will conduct a retrospective analysis of the Phase III Dry Eye Syndrome study data to determine if there is a correlation between the CF101 target, the A3 adenosine receptor, expression and patients' response to the drug. This analysis is based on recent positive data from a Phase IIb Rheumatoid Arthritis study of CF101 conducted by OphthaliX's parent company, Can-Fite BioPharma...

2013-12-19 08:26:39

PETACH TIKVA, Israel, Dec. 19, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today, that the U.S. Patent and Trademark Office granted the Company a patent which bears the Patent No. 8,541,182 and is titled "A Biological Marker for Inflammation". The patent was granted on September 24, 2013 and will be valid until 2026,...

2013-11-05 12:29:23

PETACH TIKVA, Israel, Nov. 5, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, and its subsidiary, OphthaliX Inc.(OTCQB: OPLI), jointly announced today that the U.S. Patent and Trademark Office granted a U.S. patent which bears the Patent No. 8,557,790 and is titled "A3 Adenosine receptor agonists for the reduction of intraocular pressure"....

2013-09-03 16:27:48

PETACH TIKVA, Israel, Sept. 3, 2013 /PRNewswire/ -- OphthaliX Inc. (OTC BB: OPLID), announced today that the European Patent Office issued a Certificate of Grant of Patent for European Patent No. 1778239 entitled "Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren's syndrome". This patent was granted to OphthaliX's parent and majority stockholder, Can-Fite BioPharma Ltd., and relates to OphthaliX's drug candidate CF101. Pursuant to the license...

Study Suggests Silky Brain Implants May Help Stop Spread Of Epilepsy
2013-07-25 12:04:43

NIH/National Institute of Neurological Disorders and Stroke NIH-funded study suggests role for adenosine in molecular processes involved in epilepsy Silk has walked straight off the runway and into the lab. According to a new study published in the Journal of Clinical Investigation, silk implants placed in the brain of laboratory animals and designed to release a specific chemical, adenosine, may help stop the progression of epilepsy. The research was supported by the National Institute...

2013-05-10 16:25:01

PETACH TIKVA, Israel, May 10, 2013 /PRNewswire/ -- OphthaliX, Inc. (OTC BB: OPLI), announced today that it has come to its knowledge that Professor M. Francesca Cordeiro, a Professor of Glaucoma & Retinal Neurodegeneration Studies from UCL and Imperial College in London, presented new data generated independently and unrelated to OphthaliX, validating the utilization of the A3 adenosine receptor (A3AR) agonists for lowering intra ocular pressure (IOP) and for the treatment of...

2013-04-01 12:26:11

CHARLOTTESVILLE, Va., April 1, 2013 /PRNewswire/ -- Adenosine Therapeutics, LLC, a drug discovery and development company founded in 1999, announced today that it has engaged Needham & Company to explore strategic options for Stedivaze®, a highly selective adenosine A2A agonist being developed as a pharmacological stress agent for use in Myocardial Perfusion Imaging. "We are seeking regional or global collaborators to rapidly conclude our Phase 3 clinical trials, which are more than...